Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. [PDF]
Al-Sawaf O +8 more
europepmc +1 more source
The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice. [PDF]
Arce B +10 more
europepmc +1 more source
A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma. [PDF]
Ding Y +11 more
europepmc +1 more source
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. [PDF]
Fakhri B +6 more
europepmc +1 more source
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor. [PDF]
Salles G +14 more
europepmc +1 more source
Related searches:
Resistance to Bruton Tyrosine Kinase Inhibitors
Hematology/Oncology Clinics of North AmericaTargeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire +2 more sources

